ArticleJPGN reports2026
Observational study of metastatic vulvar Crohn's disease in the pediatric population.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metastatic vulvar Crohn's disease (MVCD) is a rare cutaneous manifestation of Crohn's disease (CD), especially in pediatric patients. The objective of this study is to assess presentation, diagnosis, and treatment for pediatric MVCD in the largest cohort reported. Methods: This is a retrospective review of pediatric patients with MVCD from 2014 to 2024. Results: Twelve patients with MVCD were identified ranging from 7 to 17 years old at time of diagnosis. On average, MVCD was diagnosed 3 years after CD. Most were diagnosed with MVCD after CD but two were diagnosed concurrently and two had vulvar symptoms prior to gastrointestinal (GI). All patients were diagnosed clinically with only one patient undergoing skin biopsy (8.3%). Most common signs of MVCD included vulvar edema and linear fissures. Ninety-two percent of patients had an abdominal and pelvic magnetic resonance enterography (MRE), all with findings concerning for MVCD. All patients were treated with biologics as the main modality, along with adjunctive antibiotics (83%) and topical steroids (50%). Only 42% had documented remission of vulvar disease as determined by patient-reported symptom resolution. Conclusion: Physical exam findings and MRE are essential in diagnosis of MVCD in the pediatric population. Standardized treatment guidelines are lacking, and more than half of our patients did not achieve resolution of their vulvar symptoms even with well-controlled GI disease. The need for further research and investigation into optimal management strategies is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.